Provides home health services for patient recovery from surgery, chronic illness, or terminal conditions. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
No real growth (3% a year). Red columns mark years that ended in a loss.
The gap is $156.9M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 76.8× for every dollar this company earns in a year — a price that already assumes things go well.
Analysts' average target sits 42% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 67% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
The company’s market value is 77 times its annual profit. Even a small disappointment could hit the price hard.
Over the last 12 months, executives reported 73 sells against just 21 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.